financetom
Business
financetom
/
Business
/
Electronic Arts Swings to Fiscal Q4 Profit; Fiscal Q1, 2025 Guidance, Stock Buyback Set; Shares Drop After Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Electronic Arts Swings to Fiscal Q4 Profit; Fiscal Q1, 2025 Guidance, Stock Buyback Set; Shares Drop After Hours
May 7, 2024 4:23 PM

05:20 PM EDT, 05/07/2024 (MT Newswires) -- Electronic Arts ( EA ) reported fiscal Q4 earnings late Tuesday of $0.67 per diluted share, compared with a loss of $0.04 a year earlier.

Analysts surveyed by Capital IQ expected EPS of $0.59.

Revenue in the quarter ended March 31 fell to $1.78 billion from $1.87 billion a year earlier.

The company expects fiscal Q1 EPS of $0.73 to $0.90 a share on revenue of $1.58 billion to $1.68 billion. Analysts surveyed by Capital IQ expect EPS of $0.79.

The company expects fiscal 2025 EPS of $3.34 to $4 a share on revenue of $7.1 billion to $7.5 billion. Analysts surveyed by Capital IQ expect EPS of $4.63.

Electronic Arts ( EA ) said the board authorized a new stock repurchase program of $5 billion over three years.

The company maintained a quarterly dividend of $0.19 a share, payable June 19 to stockholders of record May 29.

Shares of the company fell 3.5% in after-hours trading.

Price: 125.65, Change: -4.59, Percent Change: -3.52

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Intensity Therapeutics Stock Cools After-Hours Following 395% Surge: What You Should Know
Intensity Therapeutics Stock Cools After-Hours Following 395% Surge: What You Should Know
Oct 30, 2025
Intensity Therapeutics Inc. ( INTS ) shares are trending on Friday. Check out the current price of INTS stock here.  Shares of the biotechnology company rallied 394.9% in Thursday's regular session after Phase 1/2 clinical trial results for INT230‑6, an intratumoral therapy combining cisplatin and vinblastine sulfate, were published in eBioMedicine, but the gains tapered in after-hours trading to $0.90,...
Corbus Pharmaceuticals Announces Pricing of Public Offering
Corbus Pharmaceuticals Announces Pricing of Public Offering
Oct 30, 2025
NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. ( CRBP ) (“Corbus” or the “Company”), an oncology and obesity company, today announced the pricing of an underwritten public offering of 4,744,231 shares of its common stock at a public offering price of $13.00 per share, and, in lieu of common stock to certain investors, pre-funded warrants...
Form 8.3 - Offeree = Big Yellow Group plc
Form 8.3 - Offeree = Big Yellow Group plc
Oct 31, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Long Pond Capital, LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...
Aalberts N.V.: Aalberts completes acquisition of Grand Venture Technology Limited
Aalberts N.V.: Aalberts completes acquisition of Grand Venture Technology Limited
Oct 30, 2025
Utrecht, 31 October 2025 Aalberts ( AALBF ) completes acquisition of Grand Venture Technology Limited Aalberts ( AALBF ) announces successful completion of the acquisition of Grand Venture Technology Limited (GVT). With its head office in Singapore, GVT operates six facilities across Singapore, Malaysia and China, generating an annual revenue of SGD 160 million in 2024 and an adjusted EBITDA...
Copyright 2023-2026 - www.financetom.com All Rights Reserved